The Johns Hopkins-led and NIH funded OUtMATCH study led to the development of Xolair, a groundbreaking drug that reduces the ...

Joseph spent his childhood dreading family gatherings. His Egyptian-American relatives would gather around the family table ...

The standard regimen of omalizumab is often modified in patients with chronic spontaneous urticaria, with several factors predicting dose adjustments.

The FDA has approved omalizumab to treat a type of hives called chronic spontaneous urticaria. It's approved to treat people 12 years of age and older who continue to get hives after taking ...